Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

George Papaxoinis, Athanasios Athanasiadis, Joseph Sgouros, Anastastios Visvikis, Maria Drizou, Emmanouil Kontopodis, Anna Koumarianou, Suzana Stojanovska, Gerasimos Aravantinos, Ippokratis Korantzis, Alex andros Ioannou, Ioannis Varthalitis, Dimitrios Doufexis, Michail Nikolaou, Georgios Lypas, Iliada Bompolaki, Athina Christopoulou, Michael Lintos, Nikolaos Tsoukalas, Davide Mauri, Nikolaos Xenidis, Panagiotis Katsaounis, Georgios Oikonomopoulos, and Ioannis Boukovinas

Hellenic Society of Medical Oncology (HeSMO), Athens, Greece

Correspondence should be addressed to George Papaxoinis; georgexoinis@gmail.com

Received 17 February 2020; Revised 14 August 2020; Accepted 7 September 2020; Published 19 September 2020

Academic Editor: Peter F. Lenehan

1. Introduction

Pancreatic cancer is a common neoplasm in the Western world, with ductal adenocarcinoma representing the dominant histology [1]. Although pancreatic cancer represents the tenth neoplasm in men and the ninth in women in incidence, it is ranked as the fourth most lethal in both sexes [2]. Pancreatic adenocarcinoma (PAC) is characterized by especially poor prognosis due to its frequently delayed diagnosis as well as its relative chemoresistance [1]. Only...
15–20% of PAC cases are surgically resectable. However, even these patients experience high relapse rate and poor prognosis [1]. Adjuvant 5-fluorouracil (5FU) or gemcitabine has improved the 5-year survival rate from 8–11% to 21–22% [3, 4], while the combination of both drugs in the form of gemcitabine-capetcitabine (GemCap) further improved 5-year survival to 29% [5], and finally, adjuvant modified FOLFIRINOX offered an unprecedented 5-year survival rate of 63% [6]. Systemic therapy of locally advanced or metastatic PAC underwent a slow progress during the last 2 decades with only few randomized trials, showing a small benefit in median survival from 4.4 months with 5FU to 5.6 months with gemcitabine [7], 8.5 months with nab-paclitaxel-gemcitabine (NPG) [8], and 11.1 months with irinotecan-oxaliplatin-5FU-leucovorin (FOLFIRINOX) [9].

These large differences in survival between studies mostly reflect the heterogeneity in the quality of surgical management, medical practice, or supportive care. Also, clinical trial patients are not usually representative of the common PAC patients usually characterized by poor performance status (PS) and comorbidities. Therefore, large-scale retrospective studies are important to describe how current progress in surgical or medical treatment has influenced patient outcomes in everyday practice. This knowledge is important in order to better organize health care provision, to better inform patients regarding prognosis, and to investigate ways to improve treatment outcomes.

The aim of the study was to investigate the pattern followed by Greek medical oncologists regarding the treatment of patients with PAC. Secondarily, the study aimed to collect data about the effectiveness of the systemic therapies in terms of survival parameters. Hence, by describing the status of care of PAC in Greece, we aimed to improve the therapeutic standards.

2. Methods

2.1. Study Design. This was an observational, noninterventional multicenter study of clinical practice in PAC patients in Greece. The study recorded clinical data from the files of 200 consecutive active patients (alive and under treatment or follow-up) for a two-year period (one year recruitment and one year observation), prospectively (from November 2015 until November 2017 approximately) from 20 oncology centers around Greece (4 belonging in oncology hospitals). The primary endpoint was to monitor and document the clinical practice and treatments in patients with PAC in Greece. Secondary endpoints were to assess progression-free (PFS) and overall survival (OS) in different lines of treatment.

The main inclusion criteria were patients’ age 18 or older, histologically or cytologically confirmed PAC, chemotherapy for PAC, alive status, and under treatment or follow-up, while exclusion criteria were the presence of other primary tumors, metastasis to the pancreas by adenocarcinoma of other primary site, and neuroendocrine pancreatic carcinoma. All patients were staged according to the 7th edition of the American Joint Committee on Cancer staging system (AJCC7). Radiological response was assessed by RECIST 1.1 criteria. However, no central radiology review was performed.

2.2. Ethics. The study was approved by local ethics committees, and all patients signed informed consent.

2.3. Statistical Analysis Plan. Descriptive statistical analysis was performed for all study data along with epidemiology methods. Continuous and categorical variables were presented with standard descriptive statistical measures, and the results were presented in tables accordingly. Median survival was calculated by the Kaplan–Meier method and compared by the log-rank test. PFS and OS were analyzed for first- and second-line treatments, as well as for different sequences of chemotherapy regimens in first- and second-line settings. PFS was defined as the time from the date of start of first- or second-line treatment to the date of progression during first- or second-line treatment, respectively, or death from other causes. OS was defined as the time from the date of start of first- or second-line treatment to the date of death from any cause. Overall PFS was defined as the time from the date of start of first-line treatment to the date of progression during second-line treatment or death from other causes. Progression-free or alive patients were censored at the last date that they were progression free or alive. Time to recurrence was defined as the time from date of surgery to the date of recurrence or last date the patient was known to remain disease free. All tests were two sided, and statistical significance was set at p < 0.05. SPSS 22.0 statistical package was used for all analyses. Due to the observational character of this study, no standard statistical method was used to determine the study sample size.

3. Results

3.1. Basic Patient Characteristics. The basic patient and tumor characteristics are demonstrated in Table 1. Median age at diagnosis was 65 years (range, 18–84), and the male-to-female ratio was 1.2. The majority had a PS Eastern Cooperative Oncology Group (ECOG) score of 0 and metastatic disease (stage IV). Also, the most common organ of distant metastasis was the liver in 112 (56.0%) patients, followed by lymph nodes in 31 (15.5%) and the peritoneum in 19 (9.5%). Finally, the vast majority of patients were diagnosed with ductal adenocarcinoma, while the rest were diagnosed with rare histological subtypes, such as acinar cell, adenosquamous, squamous, and noncystic mucinous carcinoma. Eighty (40%) patients were diagnosed with PAC before the study enrolment period (November 2015).

3.2. Radical Surgery and Adjuvant/Neoadjuvant Treatment. Fifty-one (25.5%) patients had resectable/borderline resectable tumors and underwent radical surgical resection of PAC. The stage of these tumors is described in Table 1. Of them, 41 (80.4%) patients were treated with adjuvant and/or neoadjuvant treatment, 7 (13.7%) were diagnosed with
advanced disease on postoperative imaging and underwent first-line chemotherapy, and 3 (5.9%) were followed up after operation and received first-line chemotherapy after relapsing at 11–35 months postoperatively.

Of 41 patients who received adjuvant and/or neoadjuvant treatment, 40 (78.4%) patients received adjuvant, 1 (2.0%) received neoadjuvant chemotherapy, and 4 (7.8%) patients received adjuvant radiotherapy. Among them, 37 (90.2%) relapsed. Median time to recurrence was 7.9 months (95% CI, 4.4–11.4), and median OS, 20.2 months (95% CI, 5.4–25.1). Of them, 35 patients underwent first-line chemotherapy.

3.3. First-Line Treatment. First-line chemotherapy was administered to 193 (96.5%) patients, including 45 out of 51 (88.2%) patients who had undergone radical surgery. Chemotherapy regimens are described in Table 2. A majority of patients were treated with the combination of NPG or FOLFIRINOX or gemcitabine monotherapy. Gemcitabine was administered as monotherapy more often in older patients with poorer PS. FOLFIRINOX/capecitabine-oxaliplatin-irinotecan (CAPOXIRI) and other more unusual regimens were administered more often in patients who relapsed after radical surgery because most of them had already received gemcitabine in the adjuvant setting (Table 3).

Of 157 (80.9%) patients who were assigned for disease response, 39.5% responded to the treatment (6 patients had complete response, and 56 patients, partial response [PR]). Stable disease (SD) was achieved by 54 (34.4%) patients, and progressive disease (PD) was observed in 41 (26.1%). The NPG regimen gave the numerically highest response rate, compared with FOLFIRINOX/CAPOXIRI, gemcitabine monotherapy, or other regimens (Table 4). Overall, the difference in response rate between regimens was statistically significant ($p = 0.025$).

After a median follow-up of 23.3 months (range, 0.23–72.4), 125 (64.8%) patients died and 123 (63.7%) progressed. Median OS was 14.1 months (95% CI, 11.7–16.5), and median PFS was 7.0 months (95% CI, 5.8–8.2). Median OS did not differ significantly between chemotherapy regimens (Table 5, Figure 1). In contrast, median PFS was significantly different between different chemotherapy regimens (Table 5, Figure 1). Median PFS was longer with NPG vs. gemcitabine monotherapy ($p = 0.001$), FOLFIRINOX/CAPOXIRI vs. gemcitabine monotherapy ($p = 0.003$), and other regimens vs. gemcitabine monotherapy ($p = 0.039$) (Table 5, Figure 1). Median PFS did not differ significantly between regimens other than gemcitabine monotherapy.

Of 193 patients who received first-line chemotherapy, 77 (39.9%) were diagnosed before the study enrolment period. There was a substantial difference in survival between patients diagnosed before and those during the study enrolment period. OS of patients diagnosed before the study enrolment period was significantly longer than those diagnosed during enrolment (23.0 vs. 10.4 months, respectively, $p < 0.001$). Similarly, PFS was significantly longer in patients diagnosed before the study enrolment period (9.3 vs. 6.3 months, respectively, $p = 0.014$). Median OS did not differ significantly between different chemotherapy regimens, while PFS was significantly longer with NPG and FOLFIRINOX/CAPOXIRI, in the group of patients diagnosed during study enrolment (Table 5).

3.4. Second-Line Treatment. In total, 112 (58.0%) patients received second-line treatment. The second-line chemotherapy regimens are shown in Table 6. The majority of

### Table 1: Basic patient and disease characteristics.

| Characteristics | N  | %  |
|-----------------|----|----|
| Age in years    |    |    |
| <60             | 62 | 31.0|
| ≥60             | 138| 69.0|
| Gender          |    |    |
| Male            | 107| 53.5|
| Female          | 93 | 46.5|
| ECOG performance status |    |    |
| 1               | 59 | 29.5|
| 2               | 9  | 4.5 |
| 3               | 3  | 1.5 |
| Not recorded    | 41 | 20.5|
| Histology       |    |    |
| Adenosquamous carcinoma | 3 | 1.5 |
| Others          | 4  | 2.0 |
| Not recorded    | 4  | 2.0 |
| Tumor stage (AJCC7) |    |    |
| IIB             | 118| 59.0|
| III             | 29 | 14.5|
| IV              | 118| 59.0|
| Not reported    | 2  | 1.0 |
| Total           | 200| 100.0|

AJCC7, American Joint Committee on Cancer staging 7th edition; ECOG, Eastern Cooperative Oncology Group.

### Table 2:Chemotherapy regimens that were administered as first-line treatment.

| First-line chemotherapy regimen | N  | %  |
|---------------------------------|----|----|
| Nab-paclitaxel/gemcitabine      | 113| 58.5|
| Gemcitabine                     | 16 | 8.3 |
| Gemcitabine/5-fluorouracil      | 1  | 0.5 |
| Gemcitabine/oxaliplatin         | 5  | 2.6 |
| Gemcitabine/cisplatin           | 3  | 1.6 |
| Gemcitabine/carboplatin         | 1  | 0.5 |
| Gemcitabine/erlotinib           | 1  | 0.5 |
| Gemcitabine/temsirolimus        | 1  | 0.5 |
| FOLFIRINOX                      | 36 | 18.7|
| CAPOXIRI                        | 6  | 3.1 |
| FOLFOX                          | 4  | 2.1 |
| CAPOX                           | 2  | 1.0 |
| FOLFIRI                         | 1  | 0.5 |
| CDDP/LV/5-fluorouracil          | 2  | 1.0 |
| Cisplatin/etoposide             | 1  | 0.5 |
| Total                           | 193| 100.0|

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capcitabine; CDDP, cisplatin; FOLFIRI, irinotecan/5-fluorouracil; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/5-fluorouracil.

### Table 3: Chemotherapy regimens that were administered as second-line treatment.

| First-line chemotherapy regimen | N  | %  |
|---------------------------------|----|----|
| Nab-paclitaxel/gemcitabine      | 113| 58.5|
| Gemcitabine                     | 16 | 8.3 |
| Gemcitabine/5-fluorouracil      | 1  | 0.5 |
| Gemcitabine/oxaliplatin         | 5  | 2.6 |
| Gemcitabine/cisplatin           | 3  | 1.6 |
| Gemcitabine/carboplatin         | 1  | 0.5 |
| Gemcitabine/erlotinib           | 1  | 0.5 |
| Gemcitabine/temsirolimus        | 1  | 0.5 |
| FOLFIRINOX                      | 36 | 18.7|
| CAPOXIRI                        | 6  | 3.1 |
| FOLFOX                          | 4  | 2.1 |
| CAPOX                           | 2  | 1.0 |
| FOLFIRI                         | 1  | 0.5 |
| CDDP/LV/5-fluorouracil          | 2  | 1.0 |
| Cisplatin/etoposide             | 1  | 0.5 |
| Total                           | 193| 100.0|

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capcitabine; CDDP, cisplatin; FOLFIRI, irinotecan/leucovorin/5-fluorouracil; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/5-fluorouracil.
Table 3: Association of basic patient and tumor characteristics with first-line chemotherapy regimen.

| Characteristics       | Chemotherapy regimen | Nab-paclitaxel-gemcitabine | FOLFIRINOX/CAPOXIRI | Gemcitabine | Others | p value |
|-----------------------|----------------------|----------------------------|---------------------|-------------|--------|---------|
| N (%)                 | 70                   | 36                         | 7                   | 18          | 0.003  |
| Age (years) <70       | 61.9                 | 85.7                       | 43.8                | 81.8        |
| Age (years) ≥70       | 38.1                 | 14.3                       | 56.2                | 18.2        |
| Male N (%)            | 59                   | 26                         | 6                   | 14          |
| Sex Female N (%)      | 52.2                 | 61.9                       | 37.5                | 63.6        |
| ECOG PS 0 N (%)       | 47.8                 | 38.1                       | 62.5                | 36.4        |
| ECOG PS 1 N (%)       | 41.6                 | 34.2                       | 41.7                | 23.5        |
| ECOG PS 2-3 N (%)     | 3.4                  | 2.9                        | 50.0                | 5.9         |
| Tumor stage IV N (%)  | 15.3                 | 10.0                       | 25.0                | 4.5         |
| Relapse N (%)         | 37                   | 12                         | 5                   | 4           |
| Total N (%)           | 111                  | 40                         | 16                  | 22          |

Table 4: Response to first-line treatment according to the chemotherapy regimen.

| Response | First-line chemotherapy regimen | Nab-paclitaxel-gemcitabine | FOLFIRINOX/CAPOXIRI | Gemcitabine | Others | Total |
|----------|---------------------------------|-----------------------------|---------------------|-------------|--------|-------|
| CR N (%) | 5                               | 1                           | 0                   | 0           | 6      |
| PR N (%) | 39                              | 12                          | 1                   | 4           | 56     |
| SD N (%) | 28                              | 13                          | 3                   | 10          | 54     |
| PD N (%) | 19                              | 12                          | 6                   | 4           | 41     |
| Total N (%) | 91                          | 38                          | 10                  | 18          | 157    |

Table 5: Overall and progression-free survival according to first-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

| Overall population | Diagnosed during enrolment |
|--------------------|----------------------------|
| OS (months)        | Median 95% CI | p value | Median 95% CI | p value |
| Nab-paclitaxel-gemcitabine | 14.1 10.6–17.6 | 0.429 | 12.3 8.8–15.9 | 0.125 |
| FOLFIRINOX/CAPOXIRI | 11.1 7.7–14.6 | 9.9 6.4–13.5 | 0.001 |
| Gemcitabine        | 10.4 3.0–17.7 | 6.1 0–14.8 | 0.001 |
| Other regimens     | 17.1 6.6–27.6 | 13.2 3.4–23.0 | 0.001 |

| PFS (months)       | Nab-paclitaxel-gemcitabine | 7.6 6.2–9.0 | 0.004 | 6.7 6.0–7.3 | 0.001 |
|--------------------|-----------------------------|-------------|-------|-------------|-------|
| FOLFIRINOX/CAPOXIRI | 6.9 4.1–9.7                | 6.3 4.6–8.0 | 0.001 |
| Gemcitabine        | 2.9 2.7–3.0                | 2.9 2.5–3.2 | 0.001 |
| Other regimens     | 7.0 3.2–10.8               | 5.3 1.2–9.4 | 0.001 |
patients received the combination of NPG, FOLFIRINOX/CAPOXIRI, and FOLFOX/CAPOX. Response to the treatment was assessed in 86 (76.6%) patients. A partial response was recorded in 22 (26.7%), stable disease in 32 (37.6%), and progressive disease in 31 (36.5%). Response according to the chemotherapy regimen is described in Table 7. The overall progression-free survival is shown in Figure 1.
After a median follow-up of 20.1 months (range, 0.2–48.1), 77 (69.4%) patients died and 67 (60.4%) progressed. Median OS was 8.6 months (95% CI 6.5–10.7), and median PFS was 5.5 months (95% CI 4.0–6.9 months). Patients treated with FOLFIRINOX/CAPOXIRI had numerically longer median OS than other regimens, but the difference was not significant (Table 8, Figure 2). Also, FOLFIRINOX/CAPOXIRI was associated with significantly longer median PFS than NPG (p = 0.027) (Table 6, Figure 2).

Of 116 patients who were diagnosed during the study accrual period and were treated with first-line chemotherapy, 54 (46.6%) received second-line treatment. OS of patients diagnosed before the study enrolment period was significantly longer than those diagnosed during enrolment (11.3 vs. 7.6 months, respectively, p = 0.045). In contrast, median PFS did not differ in patients diagnosed before vs. those during the study enrolment period (6.8 vs. 5.0 months, respectively, p = 0.810). Median OS and PFS did not differ significantly between different chemotherapy regimens (Table 8).

3.5. Comparison of Different Chemotherapy Sequences.
We compared the most common sequences of chemotherapy regimens (Figure 3). These were NPG as first-line followed by FOLFIRINOX/CAPOXIRI as second-line (Sequence 1, N = 22), the NPG as first-line followed by FOLFIRINOX/CAPOX as second-line (Sequence 2, N = 20), the NPG as first-line followed by other regimens as second-line (Sequence 3, N = 16), and the FOLFIRINOX/CAPOXIRI as first-line followed by NPG as second-line (Sequence 4, N = 24). All the other sequences comprised a maximum of 7 patients each and thus were excluded from the analysis due to their small sample size. No significant difference in median OS and overall PFS was observed between the chemotherapy sequences (Figure 3, Table 9). Sequence 1 and Sequence 2 compared with Sequence 4 demonstrated a trend for statistically longer median overall PFS (p = 0.044 and p = 0.054, respectively). No separate analysis of patients diagnosed during the enrolment period was performed because of their small sample size.

4. Discussion
The aim of the present prospective observational study was to describe the current medical practice in the treatment of PAC in Greece. To the best of our knowledge, this is one of the largest studies and the first prospective observational study in Greece. The reason for conducting this study was the difference that is often observed between clinical trial results and real-world practice data.
Results from large-scale registries of patients with PAC showed a median survival of only 2.5 months for stage III-IV disease [10–12]. These devastating figures could be explained by the fact that a low proportion of patients received palliative chemotherapy [10, 11, 13–15]. Contrarily, large registries including only patients treated with palliative chemotherapy demonstrated better survival rates. Registries in years 2007–2011 reported a median survival of 5–6 months [12, 16], while those published few years later demonstrated even better median survival times of approximately 7–10 months [13, 14].

The present study prospectively enrolled patients who were fit enough to receive palliative chemotherapy and showed a relatively long median survival of approximately 14 months. However, after excluding patients diagnosed with PAC before the study accrual period, median survival was reduced to approximately 10 months, which is comparable to the survival rates reported in large prospective randomized trials, namely MPACT [8] and PRODIGE4/ACCORD11 [9]. Also, two meta-analyses of studies with FOLFIRINOX reported similar median survival of 11 months [17, 18]. To our knowledge, the largest prospective clinical cohort study published so far [19], including 1174 patients with advanced unresectable PAC, showed median PFS of 4.6 months with first-line gemcitabine monotherapy, 5.6 months with NPG, and 6.3 months with FOLFIRINOX, and a median OS of 6.8 months with first-line gemcitabine monotherapy, 9.1 months with NPG, and 11.3 months with FOLFIRINOX, which are very similar to the respective large randomized trials [7–9]. Also, a Greek group reported a median survival of 10 months with a modified biweekly NPG regimen in patients treated for advanced PAC in years 2014–2017 [20].

In the current study, more than half of patients received first-line NPG and achieved an impressive median survival of 14.1 months much longer than MPACT [8]. Even after excluding patients diagnosed before study enrolment, median survival remained at high levels (12.3 months). In contrast, median survival with FOLFIRINOX/CAPOXIRI was similar to PRODIGE4/ACCORD11 results [9], but shorter than NPG. Median survival remained similar (11.1 months, 95% CI, 7.0–15.2, data not shown in Results), when the 6 patients treated with CAPOXIRI were excluded.

Notably, FOLFIRINOX is not licensed for treating PAC in Greece and needs special approval by regulatory authorities, thus limiting its availability as a treatment option. This
limitation explains the reason that only a small proportion of patients received first-line FOLFIRINOX/CAPOXIRI. Finally, in the present study, the groups that received gemcitabine monotherapy or other regimens were too small to make firm conclusions.

Imbalances in basic characteristics between treatment arms might explain differences in survival. Of note, although patients treated with first-line NPG were older and had more frequently newly diagnosed metastatic disease than patients on FOLFIRINOX/CAPOXIRI, they had numerically better survival. Moreover, despite patients treated with first-line gemcitabine monotherapy were more frequently older and of poorer PS, their median survival was better than expected. Interestingly, their median PFS was disproportionately short compared with their OS, most probably, because they benefited from second-line treatment. Specifically, of 16 patients who had received first-line gemcitabine, 7 proceeded to second-line treatment: 2 with NPG, 1 with FOLFOX, 2 with cisplatin or oxaliplatin and gemcitabine, and 2 with continuation of gemcitabine after progression. Most of them had a baseline PS ECOG score of 1 before starting first-line gemcitabine.

The present study also provided information on second-line chemotherapy results. Only few prospective studies have been published. The best studied is second-line chemotherapy after gemcitabine-based chemotherapy failure. The main options are fluoropyrimidine monotherapy, fluoropyrimidine combined with oxaliplatin, irinotecan, or both.

Table 9: Overall survival and overall progression-free survival according to second-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

|               | Median | 95% CI   | p value |
|---------------|--------|----------|---------|
| OS (months)   |        |          |         |
| Sequence 1    | 20.0   | 8.7–31.4 | 0.523   |
| Sequence 2    | 20.2   | 10.0–30.5|         |
| Sequence 3    | 13.1   | 10.8–15.3|         |
| Sequence 4    | 13.6   | 7.6–19.7 |         |
| PFS (months)  |        |          | 0.128   |
| Sequence 1    | 18.1   | 6.3–29.9 |         |
| Sequence 2    | 20.4   | 15.2–25.7|         |
| Sequence 3    | 11.9   | 9.0–14.8 |         |
| Sequence 4    | 10.3   | 7.1–13.5 |         |

Sequence 1 (N = 22): nab-paclitaxel/gemcitabine as first-line followed by FOLFIRINOX/XELOXIRI as second-line treatment. Sequence 2 (N = 19): nab-paclitaxel/gemcitabine as first-line followed by FOLFOX/CAPOX as second-line treatment. Sequence 3 (N = 14): nab-paclitaxel/gemcitabine as first-line, followed by other regimens as second-line treatment. Sequence 4 (N = 14): FOLFIRINOX/CAPOXIRI as first-line, followed by nab-paclitaxel/gemcitabine as second-line treatment; 95% CI, 95% confidence intervals; OS, overall survival; PFS, progression-free survival.
Combination chemotherapy has generally demonstrated better results than single fluoropyrimidine. A meta-analysis of clinical trials showed that there are stronger data supporting second-line irinotecan-fluoropyrimidine than oxaliplatin-fluoropyrimidine combinations [21]. An AGEO prospective study of second-line chemotherapy after first-line NPG showed that FOLFIRI (compared with FOLFOX and FOLFIRINOX) had numerically the best results in PFS (6.6 vs. 2 vs. 3.4 months, respectively) and OS (9.7 vs. 3.5 vs. 6.1 months, respectively), although differences were not significant [22]. Of note, a large prospective randomized trial NAPOLI-1 demonstrated a prolongation in median survival from 4.2 months with 5FU to 6.1 months with liposomal irinotecan as second-line treatment in PAC [23]. Two phase II studies of second-line chemotherapy with FOLFIRINOX after progression with gemcitabine-based chemotherapy led to median PFS of 3.8–5.8 months and median OS of 8.5–9.0 months [24, 25]. In the present study, the results with second-line FOLFIRINOX/CAPOXIRI compared favorably with the literature with median PFS and OS of 8 and 13 months, respectively. In conclusion, although liposomal irinotecan or irinotecan combined with fluoropyrimidine are best supported by the literature as second-line options, FOLFIRINOX has demonstrated activity that should be confirmed in the setting of prospective randomized trials.

In contrast, data on second-line gemcitabine-based chemotherapy after FOLFIRINOX failure are fewer. Gemcitabine monotherapy is an option with poor efficacy [26]. An AGEO prospective study showed better results with second-line NPG, reporting median PFS and OS of 5.1 and 8.8 months, respectively [27]. Second-line NPG after FOLFIRINOX failure was examined in a phase II trial [28]. Median PFS and OS were 3.8 and 7.6 months. Second-line NPG in the present study showed similar results with median PFS and OS of 4.5 and 8 months, respectively. Therefore, NPG is an active second-line chemotherapy regimen.

Finally, we presented the impact of different sequences of chemotherapy regimens on patient outcome. To the best of our knowledge, only few prospective studies recorded OS with specific chemotherapy sequences. AGEO prospectively recorded median survival with different chemotherapy sequences. Median OS was 10.4 months with first-line NPG followed by FOLFIRINOX, 18.4 months with first-line NPG followed by FOLFIRI, 12.3 months with first-line NPG followed by FOLFIRINOX [22], and 18 months with first-line FOLFIRINOX followed by NPG [27]. In contrast, we showed that patients receiving NPG as first-line and FOLFIRINOX/CAPOXIRI or FOLFIRI/CAPOXIRI as second-line treatment had much longer median OS than the opposite sequence. This finding might represent useful information regarding the best therapeutic strategy or might only reflect the fact that FOLFIRINOX/CAPOXIRI is too toxic and only patients with the best prognosis can tolerate them in the second-line setting. Therefore, the validity of this finding can be confirmed only by prospective randomized trials, thus avoiding potential selection bias.

The present study has some limitations. The most important is that 40% of patients were diagnosed with PAC before the study accrual period. Thus, a selection bias of pancreatic cancer survivors might explain favorable survival results. However, the exclusion of these patients did not significantly alter the difference in survival between chemotherapy regimens. Another weakness is that only a limited number of patients received first-line FOLFIRINOX. Therefore, firm conclusions cannot be made regarding the efficacy and survival results with this regimen. Finally, the lack of quality of life and treatment toxicity data is an important limitation of this prospective study.

In conclusion, this study presented useful information regarding real-world data on systemic treatment of resected and unresectable PAC in the first- and second-line settings. An important finding is the significant improvement in prognosis of patients receiving palliative chemotherapy. However, due to the nonrandomized nature of the study any comparison between different chemotherapy regimens should be regarded with caution.

Data Availability

The data used to support the findings of this study are included within the article, and the data sources are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to acknowledge Celgene for its contribution in the completion of the observational study. The study was funded by Celgene.

References

[1] T. Kamisawa, L. D. Wood, T. Itoi, and K. Takaori, “Pancreatic cancer,” The Lancet, vol. 388, no. 10039, pp. 73–85, 2016.
[2] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.
[3] J. P. Neoptolemos, D. D. Stocken, H. Friess et al., “A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer,” New England Journal of Medicine, vol. 350, no. 12, pp. 1200–1210, 2004.
[4] H. Oettle, S. Post, P. Neuhaus et al., “Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer,” JAMA, vol. 297, no. 3, pp. 267–277, 2007.
[5] J. P. Neoptolemos, D. H. Palmer, P. Ghanem et al., “Comparison of adjuvant gemcitabine and capcitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial,” The Lancet, vol. 389, no. 10073, pp. 1011–1024, 2017.
[6] T. Conroy, P. Hammel, M. Hebbar et al., “FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer,” New England Journal of Medicine, vol. 379, no. 25, pp. 2395–2406, 2018.
[7] H. A. Burris 3rd, M. J. Moore, J. Andersen et al., “Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a randomized trial,” *Journal of Clinical Oncology*, vol. 15, no. 6, pp. 2403–2413, 1997.

[8] D. D. Von Hoff, T. Ervin, F. P. Arena et al., “Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine,” *New England Journal of Medicine*, vol. 369, no. 18, pp. 1691–1703, 2013.

[9] T. Conroy, F. Desseigne, M. Ychou et al., “FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer,” *New England Journal of Medicine*, vol. 364, no. 19, pp. 1817–1825, 2011.

[10] N. Bernards, N. Haj Mohammad, M. G. H. Besselink et al., “Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in The Netherlands,” *Acta Oncologica*, vol. 54, no. 3, pp. 403–410, 2015.

[11] E. A. Burmeister, D. L. O’Connell, V. L. Beesley et al., “Describing patterns of care in pancreatic cancer,” *Pancreas*, vol. 44, no. 8, pp. 1259–1265, 2015.

[12] N. Haj Mohammad, N. Bernards, M. G. H. Besselink et al., “Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in The Netherlands,” *Journal of Cancer Research and Clinical Oncology*, vol. 142, no. 6, pp. 1353–1360, 2016.

[13] M. Zijlstra, L. G. M. van der Geest, H. W. M. van Laarhoven, V. E. P. P. Lemmens, L. V. van de Poll-Franse, and N. J. H. Raijmakers, “Patient characteristics and treatment considerations in pancreatic cancer: a population based study in The Netherlands,” *Acta Oncologica*, vol. 57, no. 9, pp. 1185–1191, 2018.

[14] J. L. Miller-Ocuin, M. S. Zenati, L. M. Ocuin et al., “Failure to treat: audit of an institutional cancer registry database at a large comprehensive cancer center reveals factors affecting the treatment of pancreatic cancer,” *Annals of Surgical Oncology*, vol. 24, no. 8, pp. 2387–2396, 2017.

[15] L. Huang, L. Jansen, Y. Balavarca et al., “Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study,” *International Journal of Cancer*, vol. 143, no. 12, pp. 3227–3239, 2018.

[16] L. Enewold, L. C. Harlan, T. Tucker, and S. McKenzie, “Pancreatic cancer in the USA: persistence of undertreatment and poor outcome,” *Journal of Gastrointestinal Cancer*, vol. 46, no. 1, pp. 9–20, 2015.

[17] P. L. S. Usón Junior, E. T. Rother, F. C. Maluf, and D. G. Bugano, “Meta-analysis of modified FOLFIRINOX regimens for patients with metastatic pancreatic cancer,” *Clinical Colorectal Cancer*, vol. 17, no. 3, pp. 187–197, 2018.

[18] H. Tong, Z. Fan, B. Liu, and T. Lu, “The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis,” *Science Report*, vol. 8, no. 1, p. 8666, 2018.

[19] S. Kokkali, E. S. Tripodaki, M. Drizou et al., “Results from the prospective German TPK clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma,” *International Journal of Cancer*, vol. 144, no. 5, pp. 981–990, 2019.

[20] S. Kokkali, E. S. Tripodaki, M. Drizou et al., “Biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer,” *In Vivo*, vol. 32, no. 3, pp. 653–657, 2018.

[21] M. B. Sonbol, B. Firwana, Z. Wang et al., “Second-line treatment in patients with pancreatic ductal adenocarcinoma: a meta-analysis,” *Cancer*, vol. 123, no. 23, pp. 4680–4686, 2017.

[22] A.-L. Pointet, D. Tougeron, S. Pernot et al., “Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: an AGEO multicenter study,” *Cancer Research and Treatment*, vol. 44, no. 3, pp. 295–301, 2020.

[23] A. Wang-Gillam, C. P. Li, G. Bodoky et al., “Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial,” *Lancet*, vol. 387, no. 10018, pp. 545–557, 2016 Feb 26, 22.

[24] J. H. Kim, S.-C. Lee, S. Y. Oh et al., “Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study,” *Cancer Communications*, vol. 38, no. 1, p. 32, 2018.

[25] M. J. Chung, H. Kang, H. G. Kim et al., “Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer,” *World Journal of Gastrointestinal Oncology*, vol. 10, no. 12, pp. 505–515, 2018.

[26] M. Sarabi, L. Mais, N. Oussaid, F. Desseigne, P. Guibert, and C. De La Fouchardiere, “Use of gemcitabine as a second-line treatment following chemotherapy with FOLFIRINOX for metastatic pancreatic adenocarcinoma,” *Oncology Letters*, vol. 13, no. 6, pp. 4917–4924, 2017.

[27] A. Portal, S. Pernot, D. Tougeron et al., “Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after FOLFIRINOX failure: an AGEO prospective multicentre cohort,” *British Journal of Cancer*, vol. 113, no. 7, pp. 989–995, 2015.

[28] N. Mita, T. Iwashita, S. Uemura et al., “Second-line gemcitabine plus nab-paclitaxel for patients with unresectable Advanced pancreatic cancer after first-line FOLFIRINOX failure,” *Journal of Clinical Medicine*, vol. 8, no. 6, p. 761, 2019.